COVID-19
Traditional Chinese medicine

TCM firm granted seal of approval during pandemic

By Yuan Shenggao | chinadaily.com.cn | Updated: 2020-07-08 19:08
A warehouse worker checks boxes of Lianhuaqingwen capsules at a Shijiazhuang Yiling Pharmaceutical facility in Shijiazhuang, capital of Hebei province, on Jan 30, 2020. [Photo/Xinhua]

Innovative muscle

Behind the marked achievements is the company's strong research and development capacities.

"Sustainable innovation is the prime engine to drive Yiling's growth," said Wu Xiangjun, general manager of the company.

The company is home to a work station, where a group of academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering work toward major technological breakthroughs and training researchers.

They, together with other domestic experts, have formed an innovative development consulting committee and made a series of achievements in biopharmaceutical R&D.

The company has developed more than 10 patented drugs, all approved to go to market, news portal iFeng's financial channel reported.

Another group of 29 new drug varieties are under development, and more than 20 reserve varieties have been selected, forming a series of patented drugs at different R&D stages.

|<< Previous 1 2 3 4   

Please feel free to contact us by sending your questions to question@chinadaily.com.cn or commenting on China Daily app. We will ask experts to answer them.

Editor's picks
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US